Clinical data | |
---|---|
Other names | LY-79907; 2-Chloro-6-methylergoline-8β-acetonitrile |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H18ClN3 |
Molar mass | 299.80 g·mol−1 |
3D model ( JSmol) | |
| |
|
Lergotrile ( INN , USAN ) is an ergoline derivative which acts as a dopamine receptor agonist. It was developed for the treatment of Parkinson's disease, but failed in clinical trials due to liver toxicity. [1] [2]
Clinical data | |
---|---|
Other names | LY-79907; 2-Chloro-6-methylergoline-8β-acetonitrile |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H18ClN3 |
Molar mass | 299.80 g·mol−1 |
3D model ( JSmol) | |
| |
|
Lergotrile ( INN , USAN ) is an ergoline derivative which acts as a dopamine receptor agonist. It was developed for the treatment of Parkinson's disease, but failed in clinical trials due to liver toxicity. [1] [2]